On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, ...
Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...
The recently passed federal defense budget for 2026 includes dedicated funding for the use of bioengineered blood vessels ...
Intermountain Medical Center participated in a trial of the first bioengineered external liver, designed to help acute liver failure patients or are not eligible for or are waiting for a transplant a ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently ...
BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results